Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LL-BMT1 in Glaucoma and Ocular Hypertension
NCT04747808Phase 2Completed
- Sponsor
- MediPrint Ophthalmics
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bimatoprost in primary open-angle glaucoma (POAG) and ocular hypertension, sponsored by MediPrint Ophthalmics. Primary endpoint: Adverse Event Rate at Day 7. Started Jan 2021; status: completed.
02
Drugs
bimatoprost
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT04747808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747808.